Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
Rheumatol Ther. 2021;8(2):903–919
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatol Ther. 2021;8(2):903–919
Front. Cell Dev. Biol. 9:630942 DOI: 10.3389/fcell.2021.630942
RMD Open 2020;6:e001374 doi:10.1136/rmdopen-2020-001374
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992
Annals of the Rheumatic Diseases, May 2020
Arthritis Care Res (Hoboken) 2020;72(8):1112-1121
Annals of the Rheumatic Diseases 2020;79:760-770
Annals of the Rheumatic Diseases 2020;79:778-786
Nat Rev Rheumatol 2020 doi.org/10.1038/s41584-020-0451-z